New stock news | Delton Technology (001389.SZ) submits application for listing on the Hong Kong Stock Exchange Main Board

06:23 15/12/2025

According to the disclosure on the Hong Kong Stock Exchange on December 14th, Guangzhou Guanghe Technology Co., Ltd. has submitted an application to the Hong Kong Stock Exchange main board, with CITIC Securities and HSBC as its joint sponsors.

According to the disclosure of the Hong Kong Stock Exchange on December 14th, Guangzhou Delton Technology Co., Ltd. (hereinafter referred to as Delton Technology) has submitted its application to float on the main board of the Hong Kong Stock Exchange, with CITIC SEC and HSBC as its joint sponsors. The prospectus shows that Delton Technology (001389.SZ) is dedicated to manufacturing key components of computing power servers, namely PCBs. The company is mainly engaged in the research and development, production, and sales of customized PCBs for computing power servers and other computing scenarios. According to data from Frost & Sullivan, based on the cumulative revenue of PCBs for computing power servers from 2022 to 2024, the company ranks third among global manufacturers of PCBs for computing power servers, and first among manufacturers of PCBs for computing power servers headquartered in mainland China.

CMOC Group Limited (03993) plans to acquire three major gold mining assets in Brazil for $1.015 billion.

Brokerage Morning Meeting Highlights | Focus on the layout opportunities of next year's policy dividends and economic direction.

LAEKNA-B (02105): The Phase III clinical trial (AFFIRM-205) of LAE002 (AFURESERTIB) for HR+/HER2- locally advanced or metastatic breast cancer has completed enrollment.

CMOC Group Limited (03993) plans to acquire three major gold mining assets in Brazil for $1.015 billion.

Brokerage Morning Meeting Highlights | Focus on the layout opportunities of next year's policy dividends and economic direction.

LAEKNA-B (02105): The Phase III clinical trial (AFFIRM-205) of LAE002 (AFURESERTIB) for HR+/HER2- locally advanced or metastatic breast cancer has completed enrollment.